About 4 000 reports

  • Active Pharmaceutical Ingredient Market: Revenue in USD billion, Biotech, Global, 2015-2023
  • Net Sales (%), by Region, 2017

The global active pharmaceutical ingredients market is expected to register a CAGR of approximately 6.2% during the forecast period (2018 - 2023). Active pharmaceutical ingredients are any substance or combination of substances used in a finished pharmaceutical product with pharmacological activity. The expenditure on research & development,...

  • Pharmaceutical
  • Company
  • Forecast
  • Market Size
  • Supply

PHARMA LEADER SERIES: ## TOP BIOSIMILAR DRUG MANUFACTURERS 2017-2027 ##.

  • Biopharmaceutical
  • Biosimilar
  • Pharmaceutical
  • China
  • Company
  • Galenica's Net Sales Share by Region (2016)
  • Galenica's Net Sales Share by Business Segments (2016)

Vifor Pharma is an international specialty pharma company that researches, develops, produces and markets its own pharmaceutical products.

  • Pharmaceutical
  • Company
  • Forecast
  • Market Segment
  • Market Size
  • 4.3 ANTARES PHARMA INC
  • 4.2.1 Company Overview

Italy Needle Free Injections Market Outlook to 2023 Summary GlobalData’s new report, "Italy Needle Free Injections Market Outlook to 2023", provides key market data on the Italy Needle Free Injections market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for Needle...

  • Pharmaceutical
  • Italy
  • Company
  • Antares Pharma, Inc.
  • Bioject Medical Technologies Inc.

PHARMACEUTICALS & HEALTHCARE, DEALS BY YEAR, 2012 TO YTD 2018 Intermountain Healthcare Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 Intermountain Healthcare Inc' s, deal volume decreased from one pharmaceuticals & healthcare d

  • Pharmaceutical
  • United States
  • Company
  • GlobalData's company
  • Intermountain Gas Company
  • provides a SWOT analysis of Roche.
  • ROCHE SWOT ANALYSIS, 2017

OBI Pharma (2016).

  • Pharmaceutical
  • Company
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • Kracie Holdings, Ltd. - Business Description
  • Name

Kracie Holdings, Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This up-to-the-minute company...

  • Pharmaceutical
  • Company
  • Forecast
  • Market Size
  • Supply
  • EARLY-STAGE DRUGS IN CLINICAL DEVELOPMENT FOR ME, 2017
  • Clinical Trial Summary for Phase II Trial, RUBY

The acquisition was completed in March 2015 and created one of the world' s TOP ## PHARMACEUTICAL COMPANIES BASED AROUND A NEW " GROWTH PHARMA" BUSINESS MODEL (ALLERGAN, PRESS RELEASE, MARCH ##, 2015).

  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Type 2 Diabetes
  • Company
  • CHF-5993 (BECLOMETHASONE DIPROPIONATE + FORMOTEROL FUMARATE + GLYCOPYRROLATE)
  • COMPANY PORTFOLIO GAP ANALYSIS IN COPD, 2015-2025

SOURCE: GLOBALDATA, PHARMA ETRACK [ACCESSED DECEMBER ##, 2016] FOR IMMEDIATE RELIEF OF SYMPTOMS, THE USUAL ADULT DOSE IS ONE PUFF (##MCG).

  • Pharmaceutical
  • Company
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Sunovion Pharmaceuticals Inc.
  • Advanced/Stage IV/Metastatic Pipeline Projects for Previously Approved Drug Molecules
  • a. Business Overview

RCC Market Patent Trend by Top Inventors Merck ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Pfizer ## ## ## ## ## ## ## ## ## ## ## ## ## ## Roche ## ## ## ## ## ## ## ## ## ## ## ## ## ## NIH ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Genentech ## ## ## ## ## ## ## ## ##

  • Pharmaceutical
  • Company
  • Argos Therapeutics, Inc.
  • AstraZeneca PLC
  • AVEO Oncology
  • LEFITOLIMOD'S CLINICAL DEVELOPMENT IN CRC
  • ENCORAFENIB'S CLINICAL DEVELOPMENT IN CRC

TABLE ##: PRODUCT PROFILE - TS-## TAHIO PHARMACEUTICALS' TS-## WAS APPROVED IN 2003 FOR THE TREATMENT OF MCRC.

  • Pharmaceutical
  • Company
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • 4.3 ANTARES PHARMA INC
  • 4.2.1 Company Overview

France Needle Free Injections Market Outlook to 2023 Summary GlobalData’s new report, "France Needle Free Injections Market Outlook to 2023", provides key market data on the France Needle Free Injections market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for...

  • Pharmaceutical
  • France
  • Company
  • Antares Pharma, Inc.
  • Bioject Medical Technologies Inc.
  • MERCK'S PSORIASIS PORTFOLIO SWOT ANALYSIS, 2015
  • PRODUCT PROFILE - REMICADE

INTERNATIONAL JOURNAL OF PHARMA WORLD RESEARCH; ##(##): ##-##.

  • Pharmaceutical
  • World
  • Company
  • Amgen Inc.
  • Merck & Co., Inc.
  • OTHER DRUGS IN PHASE II OF CLINICAL DEVELOPMENT FOR HIV, 2016
  • VIIV'S DOLUTEGRAVIR/LAMIVUDINE - PHASE III CLINICAL TRIALS

THE SAFETY AND EFFICACY OF THE NOVEL PI-BASED COMBINATION IS CURRENTLY BEING EVALUATED IN TWO PHASE III CLINICAL TRIALS IN TREATMENT-NAÏVE AND TREATMENT-EXPERIENCED HIV-##-INFECTED ADULTS (JANSSEN PHARMACEUTICALS, NCT##; JANSSEN PHARMACEUTICALS, NCT##).

  • Pharmaceutical
  • East Asia
  • Company
  • Gilead Sciences, Inc.
  • ViiV Healthcare Ltd.
  • TETRAPHASE PHARMACEUTICALS INC. N/A
  • COMPANY PORTFOLIO GAP ANALYSIS FOR HAIS AGAINST GRAM-NEGATIVE BACTERIA, 2016-2026

PharmaPoint: Healthcare-Associated Gram-Negative Infections - Global Drug Forecast and Market Analysis to 2026 Summary Bacterial infections represent a frequent occurrence in humans. Fortunately, a majority of these infections are successfully eliminated by the native and adaptive immune system. The majority of remaining...

  • Anti-Infective
  • Hospital
  • Pharmaceutical
  • Therapy
  • Company
  • OTHER PRODUCTS IN CLINICAL DEVELOPMENT FOR HCV INFECTION, 2016
  • CLINICAL DEVELOPMENT OUTSIDE 9MM, 2016

Trends; ##(##):##-##.

  • Pharmaceutical
  • Company
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • AVELUMAB'S DEVELOPMENT IN RCC
  • EXELIXIS' RCC PORTFOLIO ASSESSMENT, 2016

AVEO AND ITS MARKETING PARTNER EUSA PHARMA FILED AN MAA TO THE EMA FOR TIVOZANIB FOR THE FIRSTLINE TREATMENT OF RCC IN Q## 2016 (EUSA PHARMA, PRESS RELEASE, MARCH ##, 2016).

  • Pharmaceutical
  • Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Pfizer Inc.
  • KEY COMPANIES IN THE G/GEJAC MARKET IN THE 8MM, 2014-2024
  • SUMMARY OF RESULTS FROM A PHASE II TRIAL OF ABRAXANE

TS-## IS MARKETED BY NORDIC PHARMA UNDER THE BRAND NAME TEYSUNO.

  • Pharmaceutical
  • Company
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • 6.3 COMPANY PROFILES
  • 6.2 TRENDS IN CORPORATE STRATEGY

PUBLIC HEALTH GENOMICS; ##(##): ##-##.

  • Pharmaceutical
  • Company
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • bioMerieux S.A.
  • NOVARTIS' NSCLC PORTFOLIO ASSESSMENT, 2016
  • BMS SWOT ANALYSIS IN NSCLC, 2016

THE EFFICACY OF ZYKADIA WAS EVALUATED IN THE ASCEND-## TRIAL, A PHASE I, SINGLE-ARM, OPEN-LABEL STUDY (STUDY ##) (NOVARTIS PHARMACEUTICALS, NCT##).

  • Pharmaceutical
  • Company
  • Eli Lilly & Co.
  • Novartis AG
  • Pfizer Inc.
  • Galmed Pharmaceuticals
  • NASH Development Pipeline of Galmed Pharmaceuticals

Executive Summary Progressive numbers of Liver disorders along with rise in obesity will fuel the demand for NASH Drugs The Global NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, un-tapped market...

  • Pharmaceutical
  • Therapy
  • World
  • Company
  • Forecast

China is one of the emerging markets for pharmacovigilance, due to the growing demand for modern pharmaceuticals.

  • Pharmaceutical
  • Company
  • BioClinica, Inc.
  • PAREXEL International Corporation
  • Wipro Limited
  • 10.5 VITHERA PHARMACEUTICALS
  • Business Overview

The global human microbiome market is expected to account for nearly USD 273.40 million, registering a CAGR of about 22.6% during 2018-2025 (the forecast period). Moreover, the market is expected to reach USD 757.26 million by 2025. Increasing Incidence of Lifestyle Diseases The rising incidence of lifestyle diseases at the global...

  • Pharmaceutical
  • United States
  • Company
  • Enterome Bioscience SA
  • Synlogic, Inc.
  • Global Sales Forecast ($m) for Guselkumab, 2014-2024
  • presents the global sales forecast for guselkumab during 2014-2024.

International Journal of Pharma World Research; ##(##): ##-##.

  • Pharmaceutical
  • Company
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • presents the global sales forecast for guselkumab during 2014-2024.
  • Global Sales Forecast ($m) for Guselkumab, 2014-2024

International Journal of Pharma World Research; ##(##): ##-##.

  • Pharmaceutical
  • Company
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • presents the global sales forecast for guselkumab during 2014-2024.
  • Global Sales Forecast ($m) for Guselkumab, 2014-2024

International Journal of Pharma World Research; ##(##): ##-##.

  • Pharmaceutical
  • Company
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Global Sales Forecast ($m) for Guselkumab, 2014-2024
  • presents the global sales forecast for guselkumab during 2014-2024.

International Journal of Pharma World Research; ##(##): ##-##.

  • Pharmaceutical
  • Company
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Mitsubishi Chemical Holdings Corporation, Key Facts
  • MITSUBISHI CHEMICAL HOLDINGS CORPORATION, COMPANY OVERVIEW

The global petrochemical industry is one of the major contributors to air pollution.

  • Pharmaceutical
  • Southeast Asia
  • Thailand
  • Company
  • Bayer AG

The agreement allows TT-## to be co-marketed by Teijin Pharma Limited, the core company of the Teijin Group' s medical and pharmaceutical business, and Taisho Toyama Pharmaceutical Co., Ltd. of the Taisho Pharmaceutical Group.

  • Chemicals
  • Pharmaceutical
  • Polycarbonates
  • Company
  • Supply

ONE OF BAYER' S LARGEST ACQUISITIONS WAS OF THE PHARMACEUTICAL COMPANY SCHERING AG, ANOTHER LEADING COMPANY BASED IN GERMANY.

  • Pharmaceutical
  • Company
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.